Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Gastrointestinal · FDA Approved

Lanreotide (Somatuline Depot)

FDA-approved

How to ask your doctor
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

A synthetic octapeptide analog of somatostatin with high affinity for SSTR2 and lower affinity for SSTR5. The long-acting formulation (Autogel, sold in the US as Somatuline Depot) works through self-assembly of lanreotide into nanotubules in water, giving slow release from the injection site (PMID 25307803).

It suppresses growth hormone and GI hormone secretion and slows growth of some neuroendocrine tumors (PMID 25014687).

02 · Research summary & key findings

FDA-approved (2007) for acromegaly and later for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The CLARINET trial in nonfunctioning grade 1-2 GEP-NETs showed prolonged progression-free survival (median not reached vs. 18.0 months with placebo; hazard ratio 0.47), with no difference in overall survival or quality of life (Caplin et al., NEJM, 2014) (PMID 25014687). In acromegaly, efficacy is reported as equivalent to octreotide LAR, and the prefilled syringe allows deep subcutaneous self-injection (PMID 25307803).

03 · Regulatory status

Lanreotide (Somatuline Depot) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Lanreotide (Somatuline Depot) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.

04 · Administration routes

  • Deep subcutaneous injection (monthly)

References

  1. [1]Lanreotide in metastatic enteropancreatic neuroendocrine tumors N Engl J Med, 2014. PMID 25014687
  2. [2]Lanreotide autogel in acromegaly - a decade on Expert Opin Pharmacother, 2014. PMID 25307803

Primary literature

Related peptides in Gastrointestinal

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.